Targeting kallikreins, which are thought to lead to the clinical manifestations of Netherton Syndrome, could be an ideal approach.” Quoin CEO, Dr. Michael Myers, added, “Following our recent ...

Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX), a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has given the green light to commence an additional ...

Groundbreaking 'Whole Body' Study will be conducted by Dr. Amy Paller at Northwestern University Up to eight subjects will have QRX003 applied twice daily to greater than 80% of their body surface are ...

Amy Paller at Northwestern University Up to eight subjects will have QRX003 applied twice daily to greater than 80% of their body surface area over a 12-week period Study intended to generate data ...

Netherton Syndrome is a rare and severe genetic disorder characterized by chronic skin inflammation and scaling. QRX003 contains a broad-spectrum serine protease inhibitor targeting kallikreins ...